A large share of small molecules in current pharma company pipelines have poor oral absorption due to low aqueous solubility or dissolution rate.  Evaluating formulation approaches for increasing oral bioavailability are becoming routine early on in formulation development programs.  Not all technologies are appropriate for a given compound, and as such, selecting the appropriate bioavailability enhancing technology requires careful consideration of physicochemical properties, dose and an understanding of the root cause for poor exposure.  To learn more, view our presentation slides.
Content Type: Presentation (slides)
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center